Viva Biotech Holdings (HK:1873)
:1873
Want to see HK:1873 full AI Analyst Report?
Top Page
Viva Biotech Holdings
(1873)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$1.50
▼(-14.77% Downside)
Action:Reiterated
Date:04/24/26
The score is primarily supported by improved profitability and a stronger leverage profile, but it is held back by deteriorating 2025 cash-flow momentum and ongoing revenue decline. Technically, the stock remains in a clear downtrend (below key moving averages with negative MACD), which further pressures the overall rating, while valuation appears only moderate based on the provided P/E.
Positive Factors
Profitability recovery
Returning to net profits after loss years shows the business can generate sustainable operating earnings. For a CRO, consistent profitability supports reinvestment in lab capacity, funds venture incubations internally, reduces dilution risk and strengthens long-term operational viability.
Negative Factors
Multi-year revenue decline
Persistent top-line contraction undermines scale benefits and threatens long-term earnings growth. For a services-led CRO, shrinking revenue can reduce utilization, limit pricing leverage and constrain funding for R&D or venture deals unless client demand reverses.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability recovery
Returning to net profits after loss years shows the business can generate sustainable operating earnings. For a CRO, consistent profitability supports reinvestment in lab capacity, funds venture incubations internally, reduces dilution risk and strengthens long-term operational viability.
Read all positive factors
Viva Biotech Holdings (1873) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.07B
Dividend YieldN/A
Average Volume (3M)10.31M
Price to Earnings (P/E)18.0
Beta (1Y)2.14
Revenue Growth-12.90%
EPS Growth33.65%
CountryHK
Employees2,063
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,129,882,300
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)0.99
Price to Sales (P/S)2.28
P/FCF Ratio44.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.00Price Target Upside127.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.17B
Viva Biotech Holdings Business Overview & Revenue Model
Company Description
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purific...
How the Company Makes Money
The company primarily makes money by providing fee-for-service CRO work to external pharmaceutical, biotech, and research clients. Under this model, customers pay service fees for Viva Biotech’s research activities (e.g., discovery research suppor...
Viva Biotech Holdings Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.73B | 1.99B | 2.16B | 2.38B | 2.10B |
| Gross Profit | 655.56M | 687.40M | 738.43M | 815.68M | 650.98M |
| EBITDA | 385.38M | 428.00M | 391.01M | 436.35M | 369.94M |
| Net Income | 219.76M | 167.29M | -116.11M | -528.48M | 287.55M |
Balance Sheet | |||||
| Total Assets | 7.20B | 7.05B | 7.45B | 7.92B | 8.04B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 941.58M | 1.04B | 678.57M | 800.95M |
| Total Debt | 1.33B | 1.28B | 1.90B | 2.82B | 2.65B |
| Total Liabilities | 3.19B | 3.23B | 3.76B | 4.32B | 4.13B |
| Stockholders Equity | 4.00B | 3.80B | 3.69B | 3.60B | 3.91B |
Cash Flow | |||||
| Free Cash Flow | 88.02M | 182.32M | 195.57M | 136.72M | -487.35M |
| Operating Cash Flow | 206.04M | 373.99M | 383.40M | 386.05M | 77.83M |
| Investing Cash Flow | -93.76M | 185.90M | 439.17M | -372.80M | -868.84M |
| Financing Cash Flow | 36.61M | -657.76M | -429.50M | -143.20M | -653.16M |
Viva Biotech Holdings Technical Analysis
Negative
1.76
Price Trends
1.86
Negative
2.00
Negative
2.15
Negative
Market Momentum
-0.12
Positive
28.38
Positive
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Negative. The current price of 1.76 is above the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.86, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 28.38 is Positive, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1873.
Viva Biotech Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$38.67B | ― | 23.99% | ― | 16.65% | 0.87% | |
53 Neutral | HK$3.07B | 17.96 | 5.57% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$7.99B | 9.33 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$39.90B | -256.36 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1873
Viva Biotech Holdings
1.45
-0.21
-12.65%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.18
36.40%
HK:2096
Simcere Pharmaceutical Group Limited
10.45
0.28
2.75%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.43
0.13
3.02%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
71.15
28.95
68.60%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.32
-4.44
-41.26%
Viva Biotech Holdings Corporate Events
Viva Biotech Sets 2026 AGM to Approve Accounts, Board Changes and Share Issuance Mandate
Apr 22, 2026
Viva Biotech Holdings has convened its annual general meeting for June 26, 2026, in Shanghai to seek shareholder approval on a range of standard corporate matters. Shareholders will be asked to receive the audited financial statements for the year...
Viva Biotech Profits Rise in 2025 Despite Revenue Decline
Mar 30, 2026
Viva Biotech Holdings reported 2025 revenue of RMB 1.73 billion, down 12.9% from a year earlier, but improved profitability, with gross profit slipping only 4.6% to RMB 655.6 million and gross margin rising to 37.9% from 34.6%. Net profit increase...
Viva Biotech Sets March 30 Board Meeting to Approve 2025 Results
Mar 18, 2026
Viva Biotech Holdings has scheduled a board meeting for March 30, 2026 to review and approve the group’s audited annual results for the financial year ended December 31, 2025. The board will also decide whether to recommend a final dividend ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.